Drug Discovery World

JANUARY 20, 2023

The experimental vaccine regimen was based on ‘mosaic’ immunogens – vaccine components featuring elements of multiple HIV subtypes – with the goal of inducing immune responses against a wide variety of global HIV strains. This vaccine candidate uses a common-cold virus (adenovirus serotype 26, or Ad26) to deliver the mosaic immunogens.

Vaccine 130

Vaccine Immune Response Clinical Trials Trials 130

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community.

Immune Response 52

Immune Response Virus Disease Doctors 52

Drug Discovery Today

APRIL 15, 2021

176 volunteers will participate in the clinical trial the safety and immune response read-outs expected in Q2 2021 First subjects dosed with AKS-452, COVID-19 vaccine candidate in the Netherlands trial the vaccine is shelf-stable for 4 months at 25 degrees Celsius (77° Fahrenheit).

Clinical Trials 113

Clinical Trials Vaccine Trials Immune Response 113

Drug Discovery World

SEPTEMBER 25, 2023

The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and will evaluate the investigational vaccine for safety and its ability to elicit an immune response. “An

Vaccine 130

Vaccine Trials Animal Testing Virus 130

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) The Company announced topline preprint study results from this Phase 1/2a sub-study on July 1, 2021.

Immune Response 52

Immune Response Vaccine Clinical Trials FDA 52

The Pharma Data

OCTOBER 29, 2021

The authority was granted Marketing Authorisation by the European Commission in July 2020 and Prequalification from the World Health Organization (WHO) in April 2021. Johnson & Johnson accelerated the development of its Ebola vaccine at the onset of the 2014-2016 Ebola extremity, which caused further than deaths.

Immune Response 40

Immune Response Vaccine Clinical Trials Virus 40

The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research Government 52

The Pharma Data

JANUARY 8, 2021

This supports the notion that there’s going to be immunity for some period of time,” Perlman told the Post. There is one caveat: About 10% of people infected do see their immune response degrade. Still, he added, “from the looks of it, I wouldn’t be surprised if the immunity would last for years.”

Virus 52

Virus Vaccine Immune Response Research 52

The Pharma Data

SEPTEMBER 8, 2021

today announced that data reinforcing the potential of immunotherapies to impact clinical outcomes for patients will be featured at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress from September 16-21. About Opdivo. On March 25, 2011, the U.S.

Research 52

Research Immune Response Treatment Trials 52

The Pharma Data

JANUARY 25, 2021

The cocktail reduced viral load “with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline,” the researchers said. And safety outcomes were similar in the REGN-COV2 dose groups and the placebo group.

Immune Response 52

Immune Response Treatment Clinical Trials Hospitals 52

Drug Target Review

DECEMBER 27, 2023

This interaction inhibits inflammation and immune activation, and in particular prevents macrophages from phagocytosing and destroying cancer cells. By blocking CD24 with an antibody drug, our goal is to powerfully reactivate the anti-cancer immune response and drive therapeutic efficacy.

Immune Response 104

Immune Response Science Clinical Development Regulations 104

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. An immune response is two-tiered.

Therapies 69

Therapies Immune Response DNA Virus 69

The Pharma Data

JANUARY 11, 2021

Speaking to the Reuters Next conference, Dale Fisher, chairman of the World Health Organization’s (WHO) Outbreak Alert and Response Network, said that achievement of herd immunity in most countries is unlikely in 2021.

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Immune response was measured using immunoglobulin G (IgG) assays. Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

The Pharma Data

APRIL 15, 2022

In December 2021, Pfizer and BioNTech announced the companies would test a third 3 µg dose given at least two months after the second dose in children under age 5 and a third dose of the 10 µg formulation in children 5 to under 12 years of age. The trial enrolled children with or without prior evidence of SARS-CoV-2 infection.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

JANUARY 25, 2021

In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. government for up to 100,000 doses ( DID, Dec. 28, 2020 ).

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

JANUARY 10, 2021

phase 2b trial of their co-developed vaccine candidate because it produced only a weak immune response in older adults ( DID , Dec. 14, 2020 ) and predicted that their vaccine won’t be available until late in 2021 at the earliest. The companies announced in December that they would delay a U.S.

Vaccine 52

Vaccine Immune Response Trials FDA Approval 52

The Pharma Data

JANUARY 22, 2021

The Weinreich article also reports that the “antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group.”.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

The Pharma Data

AUGUST 6, 2020

Under the pact, AZ will transfer the vaccine’s technology to BioKangtai, which will in return reserve enough capacity to make at least 100 million doses of the shot by the end of 2020 and expand to 200 million doses per year by the end of 2021. Financial terms were not disclosed. Before the BioKangtai tie-up, it promised to provide the U.S.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

JANUARY 19, 2021

With this kind of a start, 2021 may be scorching. The company is working on a new approach to immunotherapy that uses the body’s own T-cells to create specific, potent, and durable immune responses for cancer and other life-threatening immune-mediated disease. TCR2 Therapeutics – The Cambridge, Mass.

Small Molecule 52

Small Molecule Laboratories Immune Response Trials 52

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. 14, 2020 ).

Vaccine 40

Vaccine Immune Response RNA Virus 40

The Pharma Data

JULY 6, 2021

Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. FDA for ITP.

Pharmacokinetics 52

Pharmacokinetics Therapies RNA Treatment 52

The Pharma Data

DECEMBER 12, 2020

Sanofi and GlaxoSmithKline (GSK) have decided to push back the phase 2b trial of their adjuvanted COVID-19 vaccine after finding it produced only a weak immune response in older patients, delaying the potential delivery of a vaccine that could contribute to the mass vaccination effort in the U.S. to vaccinate on demand. James Miessler.

Vaccine 52

Vaccine Immune Response Trials Research 52

Drug Discovery World

JULY 17, 2023

Unravelling the influence of these gut bacteria—commonly referred to as the bacterial gut microbiome—on drug response and immune response will bring fundamental changes to how we approach drug discovery and development, as well as patient care. REFERENCES Rosshart, S. Science (80-. ). 365, (2019) .

Immune Response 130

Immune Response Drugs Drug Development Drug Research 130

Broad Institute

OCTOBER 11, 2023

The drugs work by blocking a protein, PD-1 — which helps keep immune responses in check — and stimulating the immune system to attack tumors. By early 2021, Calico and AbbVie had launched two early-stage clinical trials testing two PTPN2 inhibitors, either as a single therapy or in combination with existing PD-1 immunotherapies.

Research 137

Research Immune Response Clinical Trials Cell Biology 137

Drug Discovery World

MAY 11, 2023

Another dangerous consequence can occur when the therapeutic or vaccine introduces proteins that can activate an uncontrolled immune response. In the case of therapeutics, the aim is usually to avoid patients’ immune responses. “Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.”

Production 130

Production Vaccine Immune Response Therapies 130

The Pharma Data

APRIL 27, 2021

Paris, April 28, 2021. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. Progress on implementation of the Corporate Social Responsibility strategy. Change at CER.

Vaccine 52

Vaccine Production FDA FDA Approval 52

The Pharma Data

JANUARY 20, 2021

20, 2021 /PRNewswire/ — INOVIO Pharmaceuticals, Inc. The offering is expected to close on or about January 25, 2021 , subject to customary closing conditions. PLYMOUTH MEETING, Pa. , This offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.

DNA 40

DNA Immune Response Disease Clinical Trials 40

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . There is hope that Moderna’s vaccine could be available by early 2021. . Each patient was given two 100 microgram doses of the vaccine 28 days apart.

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

Drug Discovery World

FEBRUARY 13, 2023

Diseases ranging from cancer to viral immune response, from cardiovascular to reproductive health, and from metabolic to nervous systems all have the potential to benefit from in-depth transcriptomics. since October 2021. HTG’s RNA profiling technology has been featured in hundreds of peer-reviewed publications in this area.

RNA 130

RNA Drugs Immune Response Therapies 130

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. The samples were stored after the researchers measured the T cell response.

Virus 52

Virus Immune Response Vaccine Research 52

Drug Target Review

JANUARY 15, 2024

The preclinical results demonstrated significant immune responses and tumour regression. Could you elaborate on the mechanisms by which these responses are initiated within cancer cells? 2021 May 7;0(0). The concept of the ‘abscopal effect’ in the 4T1 tumour model is intriguing. Reference 1. Cell [Internet].

Treatment 105

Treatment Immune Response Clinical Trials Therapies 105

Drug Target Review

OCTOBER 4, 2023

More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. This approach – immune-stimulating antibody conjugates (ISACs) – uses a payload that stimulates the innate and adaptive immune responses, recruiting tumour-fighting T cells.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

NOVEMBER 23, 2021

A team of researchers led by the University of Zurich (UZH) has now discovered another component that contributes to SARS-CoV-2 immunity – previous antibody responses to other, harmless coronaviruses. But even though the protection isn’t absolute, cross-reactive immune responses shorten the infection and reduce its severity.

Immune Response 52

Immune Response Vaccine Virus Hospitals 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. If results are positive, Phase 3 study to start in Q2 2021, with vaccine expected to be available in Q4 2021. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

In October, Scancell signed a manufacturing deal for SN14 with Cobra Biologics, a Cognate BioServices subsidiary, ahead of a planned phase 1 trial in 2021. The company, along with partners University of Nottingham and Trent University, received a British government grant to support the study. .

Clinical Trials 52

Clinical Trials Pharma Companies Vaccine Trials 52

The Pharma Data

JANUARY 22, 2021

22, 2021 — Not many people have had the opportunity to get the COVID-19 vaccine yet. An Ohio State University review of 49 vaccine studies dating back 30 years examined how stress, depression and healthy behaviors, such as exercise, can affect immune response to a vaccine. ” © 2021 HealthDay. FRIDAY, Jan.

Immune Response 52

Immune Response Vaccine Research Science 52